Kiselak Tomas: insider trades.
Kiselak Tomas reported 8 non-derivative transactions on 7 SEC ownership filings in Q3 2026: 1 open-market purchase ($12.4M) and 1 sale ($300.0M), across 3 companies.
- Transactions
- 8
- Purchases (P)
- 1
- Sales (S)
- 1
- Companies
- 3
- Name as filed
- Kiselak Tomas
Companies
| Company | Relationship | Transactions |
|---|---|---|
| Apogee Therapeutics, Inc. (APGE) | Director | 5 |
| Oruka Therapeutics, Inc. (ORKA) | Director, TenPercentOwner | 2 |
| Crescent Biopharma, Inc. (CBIO) | Director, TenPercentOwner | 1 |
Transactions
| Date | Company | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-03 | Apogee Therapeutics, Inc. | D | 51,166 | — | 0 | Form 4 |
| 2026-09-03 | Apogee Therapeutics, Inc. | D | 340,855 | — | 0 | Form 4 |
| 2026-09-03 | Apogee Therapeutics, Inc. | D | 51,166 | — | 0 | Form 4 |
| 2026-08-07 | Apogee Therapeutics, Inc. | M | 31,838 | $17 | 330,485 | Form 4 |
| 2026-08-07 | Apogee Therapeutics, Inc. | M | 10,370 | $43.85 | 340,855 | Form 4 |
| 2026-07-16 | Crescent Biopharma, Inc. | P | 853,450 | $14.5 | 3,601,316 | Form 4 |
| 2026-07-01 | Oruka Therapeutics, Inc. | S | 3,553,410 | $84.43 | 1,131,954 | Form 4 |
| 2026-07-01 | Oruka Therapeutics, Inc. | C | 3,553,410 | — | 4,685,364 | Form 4 |
Questions
What stock did Kiselak Tomas buy or sell?
Kiselak Tomas reported 8 non-derivative transactions on 7 SEC ownership filings in Q3 2026: 1 open-market purchase ($12.4M) and 1 sale ($300.0M), across 3 companies.
Is Kiselak Tomas the same person as other filers with this name?
This page covers SEC CIK 1830177 only. The SEC assigns each reporting owner a CIK, and people with the same name have different CIKs.
Source: SEC Insider Transactions Data Sets, Q3 2026. Reported as filed; we do not assess intent, performance or compliance. All filings for this CIK on SEC.gov.
Plain-text version for agents and LLMs: /insiders/kiselak-tomas-1830177.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.